PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer

(2012) G. Gullo et al.   ANNALS OF ONCOLOGY

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

(2012) Anna-Maria Jegg et al.   BREAST CANCER RESEARCH AND TREATMENT

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis

(2012) Sahar A. Saddoughi et al.   EMBO Molecular Medicine

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Phosphorylation of Eukaryotic Elongation Factor 2 (eEF2) by Cyclin A–Cyclin-Dependent Kinase 2 Regulates Its Inhibition by eEF2 Kinase

(2012) Asli A. Hizli et al.   MOLECULAR AND CELLULAR BIOLOGY

Protein Phosphatase 2A Mediates Dormancy of Glioblastoma Multiforme-Derived Tumor Stem-Like Cells during Hypoxia

(2012) Christoph P. Hofstetter et al.   PLoS One

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

(2011) E. Razis et al.   BREAST CANCER RESEARCH AND TREATMENT

Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway

(2011) Wei Li et al.   EUROPEAN JOURNAL OF CANCER

2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines

(2011) Alex J. Eustace et al.   Journal of Proteomics

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition

(2011) B N Rexer et al.   ONCOGENE

Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy

(2011) Lucia Martiniova et al.   PLoS One

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells

(2010) B. C. Browne et al.   ANNALS OF ONCOLOGY

A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma

(2010) Chao Zhang et al.   BIOMATERIALS

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells

(2010) Norma O’Donovan et al.   INVESTIGATIONAL NEW DRUGS

Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA

(2010) W. Xia et al.   MOLECULAR CANCER THERAPEUTICS

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

(2010) N. A. O'Brien et al.   MOLECULAR CANCER THERAPEUTICS

X-Linked Inhibitor of Apoptosis Protein Inhibits Apoptosis in Inflammatory Breast Cancer Cells with Acquired Resistance to an ErbB1/2 Tyrosine Kinase Inhibitor

(2010) K. M. Aird et al.   MOLECULAR CANCER THERAPEUTICS

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma

(2009) Jie Lu et al.   JOURNAL OF NEUROSURGERY

Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms

(2009) Jie Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation

(2008) A. P. Martin et al.   MOLECULAR PHARMACOLOGY

Multiple pathways regulated by the tumor suppressor PP2A in transformation

(2008) Jukka Westermarck et al.   TRENDS IN MOLECULAR MEDICINE